Literature DB >> 23970544

Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra.

Sarah M Keidel1, Rachel K Hoyles, Nick M R Wilkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23970544     DOI： 10.1093/rheumatology/ket211

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

1.  Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.

Authors:  Aurelien Justet; Sebastien Ottaviani; Philippe Dieudé; Camille Taillé
Journal:  BMJ Case Rep       Date:  2015-05-14

Review 2.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

Review 3.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08

Review 4.  Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.

Authors:  Serena Colafrancesco; Rossana Scrivo; Cristiana Barbati; Fabrizio Conti; Roberta Priori
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.